Q-omics provides the consensus-scored PIK3C2B profile across patient tissues and cancer cell-line models. PIK3C2B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PIK3C2B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PIK3C2B protein abundance shows 38,032 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where PIK3C2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3C2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3C2B survival associations across molecular data types. PIK3C2B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3C2B RNA expression–survival associations across cancer types. High PIK3C2B expression shows unfavorable associations in UVM and LUAD, but favorable associations in KIRC, HNSC, BLCA and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PIK3C2B RNA expression.
This table summarizes PIK3C2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PIK3C2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3C2B shows lower tumor expression in KICH, LUSC and BRCA and higher tumor expression in LIHC, STAD and KIRC. The KICH box plot shows higher PIK3C2B RNA expression in normal versus tumor tissue (log2 FC = −1.643, t-test p < 0.001).
This table shows molecular features associated with PIK3C2B in patient tissues and cancer cell lines. In patient samples, PIK3C2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PIK3C2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
